Search hospitals > Pennsylvania > Philadelphia
University of Pennsylvania
Claim this profilePhiladelphia, Pennsylvania 19104
Global Leader in Human Immunodeficiency Virus Infection
Global Leader in Heart Failure
Conducts research for Cancer
Conducts research for High Blood Pressure
Conducts research for Infections
1932 reported clinical trials
265 medical researchers
Summary
University of Pennsylvania is a medical facility located in Philadelphia, Pennsylvania. This center is recognized for care of Human Immunodeficiency Virus Infection, Heart Failure, Cancer, High Blood Pressure, Infections and other specialties. University of Pennsylvania is involved with conducting 1,932 clinical trials across 1,882 conditions. There are 265 research doctors associated with this hospital, such as Nimesh Desai, MD, Arati Desai, MD, Daniel Lee, MD, and Wilson Szeto, MD.Area of expertise
1Human Immunodeficiency Virus Infection
Global Leader2Heart Failure
Global LeaderStage II
Stage IV
Stage III
Top PIs
Nimesh Desai, MDUniversity of Pennsylvania6 years of reported clinical research
Studies Aortic Aneurysm
Studies Aneurysm
11 reported clinical trials
11 drugs studied
Arati Desai, MDAbrams Cancer Center of the University of Pennsylvania5 years of reported clinical research
Studies Glioblastoma
Studies Brain Tumor
10 reported clinical trials
21 drugs studied
Daniel Lee, MDWills Eye Hospital4 years of reported clinical research
Studies Glaucoma
Studies Open-Angle Glaucoma
10 reported clinical trials
18 drugs studied
Wilson Szeto, MDThe Hospital of the University of Pennsylvania5 years of reported clinical research
Studies Aortic Aneurysm
Studies Thoracic Aortic Aneurysm
10 reported clinical trials
13 drugs studied
Clinical Trials running at University of Pennsylvania
Heart Failure
Bladder Cancer
Multiple Myeloma
Portal Hypertension
Amyloidosis
Parkinson's Disease
Atrial Fibrillation
Non-Small Cell Lung Cancer
Solid Tumors
Liver Cirrhosis
Catheter Ablation + HF Therapies
for Heart Failure and Atrial Fibrillation
Heart failure (HF) with preserved left ventricular function (pEF) is difficult clinical syndrome to treat effectively with few evidence based therapies. Atrial fibrillation (AF) is now an important co-morbidity being observed in 43% of patients with HFpEF. Rhythm control has not been studied in this population. Catheter ablation and antiarrhythmic drugs are rhythm control therapies that have been used for treatment of AF without HF or HF with reduced systolic function but have not been widely applied in HFpEF. No controlled comparative evaluation has been performed in HFpEF. The introduction of wireless pulmonary artery hemodynamic monitoring has permitted optimization of HF therapy in patients with chronic HF with reduced and preserved EF. Reduction in HF hospitalizations has been observed in post hoc analyses of HFpEF patients but has not been systematically applied in AF patients with HFpEF. In this study, we propose to study both rhythm control and optimized HF therapeutic approaches in an AF with HFpEF study population in a pilot study using a sequential two phase randomized controlled clinical trial design.
Recruiting3 awards Phase 413 criteria
Calcium Channel Blocker + Beta Blocker
for Heart Failure
Heart failure with preserved ejection fraction (HFpEF) is a critical public health problem. Heart failure (HF) affects over 5 million adults in the United States (US), and is a major source of morbidity, mortality, and impaired quality of life. Approximately half of individuals with HF have a preserved left ventricular (LV) ejection fraction (EF), termed HF with preserved EF (HFpEF). While there are several effective pharmacologic therapies for HF with reduced ejection fraction (HFrEF), none have been identified for HFpEF. Hypertension, which is present in approximately 80% of individuals with HFpEF, is the foremost modifiable risk factor for the development and progression of HFpEF. Despite the clinical importance of hypertension in HFpEF, there is limited information on how common antihypertensive agents, particularly calcium channel blockers (CCBs) and β-blockers, effect pathophysiologic mechanisms of HFpEF. This is a mechanistic investigation of the role of dihydropyridine CCBs compared to β-blockers (commonly used antihypertensive agents in clinical practice) in targeting key physiologic abnormalities in HFpEF.
Recruiting3 awards Phase 46 criteria
Sitagliptin
for Type 2 Diabetes with Genetic Mutation
This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact DPP4 substrates compared to during placebo and compared to matched controls.
Recruiting2 awards Phase 43 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Pennsylvania?
University of Pennsylvania is a medical facility located in Philadelphia, Pennsylvania. This center is recognized for care of Human Immunodeficiency Virus Infection, Heart Failure, Cancer, High Blood Pressure, Infections and other specialties. University of Pennsylvania is involved with conducting 1,932 clinical trials across 1,882 conditions. There are 265 research doctors associated with this hospital, such as Nimesh Desai, MD, Arati Desai, MD, Daniel Lee, MD, and Wilson Szeto, MD.
Where is University of Pennsylvania located?
**Hospital of the University of Pennsylvania Directions:**
- To reach the Hospital of the University of Pennsylvania, take I-676 West to I-76 East (Schuylkill Expressway) and exit at 346-A (South Street). Turn right onto South Street to enter the campus.
**Pennsylvania Hospital Location:**
- Pennsylvania Hospital is situated at 800 Spruce Street, with the main entrance located on 8th Street.
Who should I call to ask about financial aid or insurance network?
For financial assistance at the University of Pennsylvania Hospital:
- Contact: 800-406-1177 or request online via MyLGHealth.
- Insurance inquiries: Contact Penn Medicine's insurance and billing department at 800-406-1177.
- Availability: Monday to Friday, 8:00 am to 6:00 pm EST; Saturday, 9:00 am to 1:00 pm EST.
What insurance does University of Pennsylvania accept?
The University of Pennsylvania Hospital accepts a wide range of insurance plans, including but not limited to Medicare Advantage, Pennsylvania Medical Assistance Managed Care (Medicaid), and Community HealthChoices (CHC). For Penn Cutaneous Pathology services, accepted insurances extend to Aetna, AmeriHealth, Keystone Health Plan East, and many others. Additionally, the Penn Student Insurance Plan (PSIP) through Aetna Student Health is available for most graduate and professional program students, meeting Penn's insurance requirements.
What awards or recognition has University of Pennsylvania received?
The University of Pennsylvania Hospital in Philadelphia is renowned for its clinical research studies, focusing on the prevention, diagnosis, and treatment of diseases. Its research laboratory specializes in imaging analytics, machine learning, pattern recognition, and computational imaging. This work is supported by the Pennsylvania Department of Health and NIH through multiple grants.